OBJECTIVES: (1) To investigate whether modulation of the cannabinoid type 1 receptor (CB1R) directly regulates the production of adiponectin (ApN) and other adipokines in omental adipose tissue (OAT) of obese subjects, (2) to establish in which cellular fraction of OAT the effects of CB1R blockade take place and (3) to unravel the underlying mechanisms. SUBJECTS AND METHODS: OAT was obtained from 30 obese subjects (body mass index: 40.6±1.3 kg m À 2 ) undergoing abdominal surgery. Primary cultures of explants or of freshly isolated adipocytes or stromal-vascular cells (SVCs) were used. RESULTS: In OAT explants, the CB1R blocker Rimonabant upregulated ApN gene expression. mRNA abundance of omentin that exhibits insulin-sensitizing properties was upregulated as well. Conversely, mRNA levels of two pro-inflammatory cytokines, macrophage inflammatory protein (MIP)-1b and interleukin (IL)-7 were downregulated. We next examined where these effects took place within OAT. CB1R expression was similar in both cellular fractions. In isolated mature adipocytes, blockade of CB1R reproduced the increase of ApN mRNA and the decrease of IL-7 mRNA, while inducing a rise of ApN secretion into the medium. In isolated SVC, gene expression of omentin, which is restricted to this fraction, was augmented, while that of MIP-1b was diminished. Finally, we deciphered the mechanisms leading to ApN regulation by the endocannabinoid system (ES). We first established that ApN regulation was actually mediated by the CB1R: ApN gene expression was upregulated by Rimonabant and downregulated by the CB1R agonist arachidonyl-2-chloroethylamide (ACEA). Upregulation of ApN by Rimonabant was unaltered by inhibiting cAMP production. However, downregulation of ApN by ACEA was fully reversed by an inhibitor of p38 mitogen-activated protein kinase (p38MAPK) and ACEA increased p38MAPK phosphorylation. CONCLUSIONS: Blockade of CB1R attenuates the inflammatory state in both cellular fractions of OAT either by increasing ApN and omentin production or by decreasing mRNAs of MIP-1b and IL-7. ApN regulation by the ES partly involves p38MAPK.
INTRODUCTION
Obesity is locally characterized by adipose tissue inflammation and dysregulation of adipokine production with oversecretion of deleterious regulatory peptides and hyposecretion of defensive ones, like adiponectin (ApN).
1,2 Such a dysregulation triggers the development of a systemic low-grade pro-inflammatory state, which is considered to build the common soil for the development of obesity comorbidities and the metabolic syndrome. 1, 3, 4 Preferential accumulation of central-omental rather than subcutaneous fat appears to be a stronger risk factor for this adverse health profile. 1 The endocannabinoid system (ES), consisting of the cannabinoid type 1 receptor (CB1R) and of endogenous lipid-derived ligands, modulates energy homeostasis through central orexigenic effects and peripheral metabolic effects on several organs including adipose tissue where energy storage is increased. 5, 6 Obese subjects exhibit higher endocannabinoid levels in visceral fat and serum than lean controls 7, 8 and also show higher endocannabinoid levels in visceral than in subcutaneous fat. 9 A strong activation of the ES might thus be considered as a driving force leading to-or associated with-central obesity. 10 Treatment of obese patients with the selective CB1R blocker Rimonabant promoted significant decreases of body weight and waist circumference (a marker of abdominal adiposity) as well as improvements in cardiovascular and metabolic risk factors. 11 Parts of these improvements have been ascribed to a rise of circulating ApN levels. This rise was partly independent of weight loss and suggested specific improvement of adipose tissue function. 12 In line with this observation, Rimonabant increased the expression of ApN both in adipose tissue of rodents treated in vivo and in murine 3T3-F442A adipocyte line in vitro. 13 However, the peripheral effects of cannabinoids have been poorly investigated in human adipose tissue. Few reports yielded controversial data on adipokine release by human fat cells. [14] [15] [16] These experiments were carried out on adipocytes differentiated in vitro from stromal precursors, which were isolated mainly from subcutaneous fat of non-obese subjects, 15, 16 then submitted to pharmacological doses of adipogenic cocktails. However, omental rather than subcutaneous fat, as well as obesity are linked to the metabolic syndrome and abnormal endocannabinoid tone. Additionally, differentiation of fat cells within an in-vivo context together with preserved cell interactions may be a prerequisite for optimal adipokine gene expression.
Besides downregulation of ApN, we like others have shown that several adipokines are oversecreted by omental adipose tissue (OAT) of obese subjects and could contribute to metabolic and cardiovascular disorders as well. 18 Both adipocytes and stromalvascular cells (SVCs; that is, non-fat cells) contribute to such adipokine deregulation in human obesity. 18 Yet, the potential direct role of the ES on the SVC fraction has never been addressed. Moreover, the mechanisms underlying a potential regulation of adipokines by the ES are still unexplored.
The aims of this work were (1) to assess whether modulation of CB1R directly regulates the production of ApN and other adipokines in OAT of obese subjects, (2) to establish in which cellular fraction of OAT the effects of CB1R blockade take place and (3) to unravel the underlying mechanisms.
SUBJECTS AND METHODS Subjects
OAT was obtained from 30 obese subjects undergoing bariatric surgery (vertical banded gastroplasty) after an overnight fast (Table 1) . Patients were not treated with hormones (for example, glucocorticoids; except for insulin for one of them), non-steroid anti-inflammatory drugs or any medications known to influence fat mass or metabolism (for example, thiazolidinediones, systemic and non-specific modulators of adrenergic receptors).
For each patient, blood was collected in the fasting state before surgery. As shown in Table 1 , these patients were severely obese, had higher systolic blood pressure, fasting glycemia, low-density lipoprotein cholesterol and C-reactive protein levels than the recommended or normal values and women had lower high-density lipoprotein cholesterol concentrations. Eight patients were diagnosed as type 2 diabetic and were treated by diet and/or oral anti-diabetic agents or by insulin for one of them. Two-thirds of the patients met criteria of the metabolic syndrome as defined by a joint scientific statement. 19 For each culture, explants or cells from only one subject were used. Due to the limited tissue availability, not all data could be generated from all patients.
The study protocol had the approval of the local Ethical Committee of the Cliniques Universitaires Saint-Luc.
Cell or adipose tissue culture
We used established protocols to study the production of adipokines by fragments or isolated cells from OAT. 18, 20, 21 Under those experimental conditions, neither tissue fractionation nor culturing per se did alter adipokine expression levels. 18 Briefly, OAT biopsies were transported to the laboratory within 5-10 min after sampling. 20 Samples were fractionated into adipocytes and SVC by collagenase treatment, as reported. 18, 20 This yields two high purity fractions. 18 Adipocytes (150 ml packed cells) and SVCs (150 ml per 3.6 g initial tissue) were cultured in MEM supplemented with 10% fetal calf serum and 1/500 (v/v) antibiotics (Primocin InvivoGen, Toulouse, France), as described. 18 Cells were allowed to stabilize for 1 h in this medium; next, the medium was renewed and cells were cultured for another 24 h with or without SR141716 (Rimonabant, a selective CB1R antagonist; Sanofi-Aventis, Diegem, Belgium) or a selective CB1R agonist ACEA (arachidonyl-2-chloroethylamide, Tocris Bioscience, Ellisville, MO, USA). In some experiments, adipocytes were cultured for 25 h with specific inhibitors of kinases (c-Jun NH 2 -terminal protein kinase (JNK), SP600125; p38 mitogen-activated protein kinase (p38MAPK), SB203580; Extracellular Signal-Regulated kinases 1/2 (ERK1/2), PD 98059) or of adenylate cyclase (MDL-12,330A), before the addition of ACEA or SR141716 for the last 24 h. All inhibitors were from Calbiochem (La Jolla, CA, USA); the concentrations used were based on those recommended by the manufacturer or previously published in the literature. [21] [22] [23] [24] Because SR141716, SP600125, SB203580 and PD 98059 were dissolved in dimethylsulfoxide and ACEA was dissolved in ethanol, dimethylsulfoxide or ethanol was used as vehicle for the control conditions. The final concentrations of dimethylsulfoxide or ethanol in medium were o0.1%. In our first experiments, adipose tissue explants (2-3 mm 3 fragments, 400 mg tissue) were also cultured for 24 h, as described for cellular fractions. 20, 25 After culturing, cells or explants were harvested and frozen at À 80 1C. Aliquots from adipocyte culture medium were also saved and stored at À 20 1C.
RNA extraction and real-time quantitative PCR (RTQ-PCR)
Total RNA from cells or tissue was extracted by using TriPure Isolation Reagent (Roche Diagnostics, Vilvoorde, Belgium). In all, 0.2-2 mg of total RNA was reverse transcripted as described. RTQ-PCR primers were designed by using Primer Express Software (Applied Biosystems, Carlsbad, CA, USA; see Table 2 ). In all, 4-40 ng of total RNA equivalents was amplified with iQSyber Green Supermix (Bio-Rad Laboratories, Nazareth, Belgium) containing 200 nM of each specific primer using iCycler iQ Real Time PCR detection System (Bio-Rad Laboratories). Briefly, the threshold cycles (CT) were measured in duplicate. DCT values were calculated in every sample for each gene of interest as follows: CT gene of interest À CT reporter gene with TATA box-binding protein (TBP) as the reporter gene. Relative changes in the expression level of one specific gene (DDCT) were calculated as DCt of the test group minus DCT of the reference group, and then presented as 2 À DDCT (Delaigle et al.
26
).
Determination of ApN concentration in medium by RIA ApN concentrations were measured in medium from cultured adipocytes by using a commercially available RIA kit (Linco Research, Nuclilab, The Netherlands). This kit does not discriminate between the different forms of ApN. Samples from diluted medium (1:1) were run in duplicate. 
Glucose homeostasis
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Western blot
Adipocytes were homogenized in a lysis buffer (Cell Signaling Technology, BIOKÉ, Leiden, The Netherlands) supplemented with 1% protease inhibitor cocktail (Roche Diagnostics). In all, 20 mg proteins were dissolved in Laemmli buffer, subjected to SDS-PAGE under reducing and heatdenaturating conditions and then transferred onto PVDF membranes. The following antibodies were used for immunodetection: anti-phosphop44/42 MAPK (Erk1/2) (Thr202/Tyr204), anti-phospho-SAPK/JNK (Thr183/ Tyr185) and anti-phospho-p38MAPK (Thr180/Tyr182). Each antibody was used according to manufacturer's instructions (Cell Signaling Technology, BIOKÉ). Signals were revealed by enhanced Chemiluminescence. Band intensities were quantified by scanning densitometry (Gel-Doc2000, Bio-Rad Laboratories, Ltd, Hemel Hempstead, UK), analyzed with Quantity One (Bio-Rad Laboratories Ltd) and normalized to Actin (Sigma-Aldrich, Bornem, Belgium) band intensity.
Presentation of the results and statistical analysis
The results are presented as mean values ± s.e.m. for the indicated numbers of patients. Comparisons between different conditions within a same group were made using two-tailed paired Student's t-test (two conditions) or repeated analysis of variance (several conditions) followed by the Dunnett's or Newman-Keuls' test, when appropriate. Differences were considered statistically significant at Po0.05.
RESULTS

Effect of CB1R blockade on adipokine gene expression in cultured explants
We first investigated the effects of blocking CB1R with Rimonabant on whole adipose tissue of obese patients. Rimonabant for 24 h upregulated ApN gene expression by B40% in omental Adiponectin  GCAGAGATGGCACTCCTGGA  CCCTTCAGTTCCTGTCATTCC  101  CB1R  CCCTCTTGTGAAGGCACTGC  GCGGCCCTGTGAACACTG  101  GRO  GCCAGTGCTTGCAGACCCT  GGCTATGACTTCGGTTTGGG  101  IL-7  GCACTGGTGATTTTGATCTCCA  CAGGGCAGCTGGTTTTCTTC  101  Leptin  AAGCTGTGCCCATCCAAAAA  GGAGGAGACTGACTGCGTGTG  101  MIP-1b  GCTGCTTTTCTTACACCGCG  GGTTTGGAATACCACAGCTGG  101  Omentin  CCGGTGATCCCTGTGGTCTA  AACTGAACAAATCCCGCAGTG  101  RANTES  AGCCCTCGCTGTCATCCTC  GGGCAATGTAGGCAAAGCAG  101  TIMP-1  TGGCATCCTGTTGTTGCTGT  TGATGACGAGGTCGGAATTG  101  TNF-a  CTCTTCTGCCTGCTGCACTTT  GATGATCTGACTGCCTGGGC  101  TPO  ATGGAGGAGACCAAGGCACA  GATGAGAGGCAAGTGGGTCC  101  TBP  CCCCATGACTCCCATGACCC  ACGAAGTGCAATGGTCTTTAGGT Figure 1 . Gene expression of adipokines in explants of human OAT treated with Rimonabant. Explants of OAT form obese subjects were cultured with or without 10-100 nM Rimonabant (Rim) for 24 h. Adipokine mRNA levels were quantified by RTQ-PCR, normalized to the levels of TBP (used as reporter gene) and are presented as relative expression compared with control (untreated) explants. Results are mean ± s.e.m. for 8-12 obese subjects. *Po0.05 vs control conditions. adipose explants (Figure 1 ). mRNA abundance of omentin which, like ApN, exhibits insulin-sensitizing properties and is decreased in obesity 27 was upregulated as well (approximately þ 78%; Figure 1 ). We further examined the effects of Rimonabant on several other adipokines that we have previously identified as overproduced by OAT in human obesity 18 : three chemokines (Growth-Related Oncogen factor, Regulated upon Activation Normal T cells Expressed and Secreted, macrophage Figure 1 ). mRNA levels of the other adipokines (Regulated upon Activation Normal T cells Expressed and Secreted, Growth-Related Oncogen factor and thrombopoietin) were not modified by CB1R blockade. Likewise, gene expression of leptin and tumor necrosis factor-a was not affected (data not shown, n ¼ 7-8 patients/group).
Effect of CB1R blockade on adipokines in mature adipocytes and SVC We next examined where the effects of Rimonabant on adipokine production took place within OAT. It is of note that CB1R was similarly expressed in both cellular fractions of OAT (relative mRNA abundance: 1.0 ± 0.5 in adipocytes vs 1.1 ± 0.6 in SVC, n ¼ 9). In isolated mature adipocytes, blockade of CB1R reproduced the increase of ApN mRNA and the decrease of IL-7 mRNA while inducing a moderate but significant increase of ApN secretion into the medium ( þ 20%; Figures 2a and b) . In isolated SVC, gene expression of omentin, which is known to be restricted to this fraction 27 was augmented like that of TIMP-1, while MIP-1b mRNA was diminished (Figure 2c ).
Mechanisms involved in ApN regulation by the ES To decipher the mechanisms leading to ApN regulation by the ES, we investigated candidate signaling pathways in adipocytes.
We first established that ApN regulation by the ES was actually mediated by the CB1R. Indeed, while ApN gene expression was upregulated by the selective CB1R antagonist Rimonabant, its expression was downregulated by using a specific agonist of CB1R, ACEA (Figure 3a) .
Next, we investigated post-CB1R signaling pathways. The classic post-receptor signal transduction pathways of CB1R activation include inhibition of cAMP production and stimulation of MAPKs, including p38MAPK, JNK and ERK1/2 in a variety of cell types. 28 We thus investigated whether the stimulation of ApN gene by Rimonabant resulted from a rise of cAMP levels. The upregulation of ApN mRNA by Rimonabant was unaltered by using the adenylate cyclase inhibitor MDL-12330A (Figure 3b ). Yet, this inhibitor was effective as it prevented the rise of cAMP levels caused by Rimonabant in adipocytes (Figure 3b) . Taken together, these data suggest that cAMP may not be involved in ApN regulation by the ES. We next blocked components of MAP kinase signaling by using specific inhibitors of p38MAPK (SB203580), ERK1/2 (PD98059) and JNK (SP60025). These inhibitors were tested during stimulation of CB1R signaling. This strategy was chosen because basal phosphorylation of MAPK components was rather low and it thus appeared to be easier to disclose an increase (rather than a decrease) of phosphorylation levels. None of the inhibitors used alone altered ApN gene expression (not shown). Downregulation of ApN expression by ACEA was fully reversed by the selective inhibitor of p38MAPK (Po0.01 for ACEA vs ACEA þ SB), while the differences between ACEA alone vs ACEA þ SP or ACEA þ PD did not reach statistical significance (Figure 4a ). This suggests that p38MAPK pathway could mediate CB1R-regulated ApN expression. Western blot analysis further showed that stimulation of CB1R with 1 mM ACEA did actually increase by B50% p38MAPK phosphorylation (Po0.05; Figure 4b ) and only slightly increase ERK1/2 phosphorylation in adipocytes (B15%, Po0.05; Figure 4c ). JNK phosphorylation was unaffected (data not shown).
DISCUSSION
We show that CB1R modulation alters adipokine production both in explants and in each cellular fraction isolated from OAT of obese subjects. Previous work on human adipocytes differentiated in vitro (mainly from the subcutaneous depot and from non-obese subjects) yielded controversial data. On one hand, neither treatment with a CB1R agonist nor with a CB1R blocker affected ApN expression, 14 in line with the lack of relationship between human adipose tissue CB1R expression and ApN production. 29 On the other hand, a synthetic cannabinoid upregulated proinflammatory adipokines in human fat cells, 15 while the selective CB1R blocker Rimonabant restored to basal levels the secretion of ApN, which was downregulated by lipopolysaccharide co-treatment. 16 Herein, we unambiguously show that a selective CB1R agonist (ACEA) decreased ApN expression, while a selective CB1R blocker upregulated ApN and concurrently downregulated the expression of several pro-inflammatory adipokines in both cellular fractions of OAT. The fact that we were able to disclose an effect of CB1R blockade even in basal conditions may be explained by the already enhanced cannabinoid tone in omental fat of obese subjects. We further demonstrated that CB1R blockade alters the adipokine production by SVC as well. This is novel information as all the studies performed so far have focused on the adipocyte fraction. In line with our data, the mRNA abundance of CB1R was similar in both cellular fractions of human OAT. It should be mentioned that ACEA may have a weak affinity for CB2R 30 and that Rimonabant may be an agonist of the orphan G protein-coupled receptor GPR55. 31 However, action of these compounds through these alternate receptors is unlikely in our study for two reasons. First, such action requires much higher concentrations of each compound that those used herein. 32 Second, the inverse regulation of ApN by ACEA and Rimonabant strongly supports the concept that ApN production is actually CB1R regulated.
Besides ApN, other adipokines were regulated by CB1R blockade. We found that Rimonabant upregulated the expression of omentin and TIMP-1 in SVC, while downregulating that of MIP-1b and IL-7 in SVC and adipocytes, respectively. All these adipokines are overproduced in obesity 18 except for omentin, which is decreased like ApN. 33 Omentin is a novel adipokine preferentially produced by visceral adipose tissue, with a main contribution of SVC. 27 This adipokine exhibits insulin-like properties in human adipocytes, 27 inhibits vascular inflammation 34 and may exert cardiovascular protection. 35 The increase of omentin may thus represent a novel benefit of CB1R blockade in the context of the metabolic syndrome. TIMP-1 was also upregulated by CB1R blockade. Matrix metalloproteinases and their tissue inhibitors (TIMPs) may have a role in development of obesity by contributing to adipogenesis and extracellular matrix degradation. However, the exact role of TIMP-1 on fat mass development and adipogenesis is still unclear: some studies reported enhanced adipocyte differentiation and hypertrophy, 36, 37 while others did not observe any effect 38 or reported impaired differentiation. 39 CB1R blockade also downregulated two adipokines: IL-7 and MIP-1b. IL-7 is a potent pro-inflammatory cytokine, known for its critical role in T-cell development and survival and its role in B-cell development. 40 MIP-1b is a chemokine, which is crucial in recruiting macrophages and other pro-inflammatory cells. 41 Although the function of these adipokines on adipose tissue is still poorly documented, both may have a role in initiating and shaping the immune-inflammatory responses in this tissue. The adipokines regulated by CB1R modulation may thus represent novel mechanisms involved in the peripheral metabolic, immune and cardiovascular effects of ES in human obesity.
Major mediators of CB1R involve inhibition of adenylyl cyclase and regulation of ion channels as well as phosphorylation of MAPKs, such as p38MAPK, ERK1/2 and JNK. 28 However, the mechanisms by which CB1R regulates ApN have never been studied in human adipocytes. There is only one report indicating that Rimonabant increased ApN expression and concurrently decreased ERK1/2 activity in a murine preadipocyte cell line. 42 We therefore examined whether cAMP and MAPKs were involved in the regulation of ApN in human mature adipocytes. CB1R blockade increased cAMP production, while CB1R stimulation increased the phosphorylation of p38MAPK and also possibly that of ERK1/2 without affecting JNK. cAMP is a well-known potent inhibitor (not a stimulator) of ApN production in human visceral adipose tissue. 43 This fact may be a priori difficult to reconcile with the observation that CB1R blockade increased both cAMP and ApN levels. However, the upregulation of ApN was unaltered by inhibiting cAMP production, ruling out a potential involvement of cAMP in this observation. Thus, CB1R blockade upregulated ApN in spite of rising cAMP. We also found that CB1R activation downregulated ApN gene expression and that this effect was reversed by specific inhibitors of p38MAPK. These data were confirmed by CB1R-induced phosphorylation of p38MAPK. Our finding is consonant the report that ACEA reduced mitochondrial biogenesis also through activation of the same component (that is, p38MAK) in mouse adipocytes. 44 Taken together, these data indicate that p38MAPK could mediate the effects of CB1R on ApN regulation.
In summary, the ES directly regulates the immune balance of OAT in human obesity. Specifically, blockade of CB1R attenuates the inflammatory state in both adipocytes and SVC either by increasing ApN and omentin production or by decreasing MIP-1b and IL-7. ApN regulation by the ES partly involves p38MAPK.
